Date: 2012-01-17
Type of information: Development agreement
Compound: molecular companion diagnostic test intended to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC)
Company: Ventana Medical Systems (USA - a member of Roche Group - Switzerland) Bayer (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease: undisclosed
Details: Ventana Medical Systems has entered into a strategic collaboration agreement with Bayer Pharma AG to develop a molecular companion diagnostic test intended to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC). Ventana\'s diagnostic immunohistochemistry platform aims to analyze the expression level of certain tumor targets serving as biomarkers in clinical studies for patient selection. This will support the development of novel products in the field of oncology therapy and underscores Roche\'s commitment to personalized healthcare.
Under the terms of the Bayer agreement, Ventana will initially develop, manufacture and commercialize a companion diagnostic test for one of Bayer\'s ADCs. Over a period of five years, both parties may initiate further development projects to develop molecular diagnostic tests in support of additional targeted cancer therapy drugs.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
